Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis - 26/05/21
, Tomo Ando, MD c, Alexandros Briasoulis, MD, PhD d, Hisato Takagi, MD, PhD e, Sripal Bangalore, MD, MHA fRiassunto |
Background |
Potent P2Y12 inhibitors reduce cardiovascular events but increase bleeding in patients presenting with acute coronary syndrome (ACS). Elderly patients are at increased risk of bleeding and whether the benefit-risk ratio of potent P2Y12 inhibitors remains favorable is not known.
Objectives |
To investigate the efficacy and safety of potent P2Y12 inhibitors versus clopidogrel in elderly patients with ACS.
Methods |
PUBMED and EMBASE were searched through July 2020 for randomized control trials (RCTs) or subgroup analyses of RCTs investigating potent P2Y12 inhibitors (prasugrel or ticagrelor) or clopidogrel in elderly (age ≥ 65 years) patients with ACS. The primary outcome was major adverse cardiovascular events (MACE).
Results |
Our search identified 9 RCTs with a total of 10,792 elderly patients. When compared with clopidogrel, potent P2Y12 inhibitors had similar risk of MACE (hazard ratio (HR): 0.94; 95%; confidence interval (CI) [0.85-1.06], P = .31, I2 = 9%), all-cause mortality (HR: 0.89; 95% CI [0.74-1.07], P = .22, I2 = 29%), reduced the risk of cardiovascular death (HR: 0.82; 95% CI [0.68-0.98], P = .03, I2 = 16%) but increased the risk of major bleeding (HR: 1.27; 95% CI [1.04-1.56], P = .02, I2 = 0%). In a subgroup analysis, ticagrelor reduced all-cause mortality (HR: 0.73; 95% CI [0.55-0.98]) and cardiovascular death (HR: 0.70; 95% CI [0.54-0.90]) compared with clopidogrel.
Conclusions |
Among elderly patients with ACS, potent P2Y12 inhibitors reduce cardiovascular death but increase bleeding with no difference in MACE or all-cause death when compared with clopidogrel. Further RCTs are needed to refine P2Y12 inhibitor selection for elderly patients with ACS.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Acute coronary syndrome, Ticagrelor, Prasugrel, Clopidogrel, Elderly, P2Y12 inhibitor
Abbreviations : ACS, BARC, CI, DAPT, HR, MACE, PCI, PLATO, PRISMA, RCT, RR, TIMI
Mappa
Vol 237
P. 34-44 - Luglio 2021 Ritorno al numero
Articolo precedente
- Transcatheter aortic valve replacement in low-risk patients: 2-year results from the LRT trial
- Ron Waksman, Rebecca Torguson, Giorgio A. Medranda, Corey Shea, Cheng Zhang, Paul Gordon, Afshin Ehsan, Sean R. Wilson, Robert Levitt, Chiwon Hahn, Puja Parikh, Thomas Bilfinger, David Butzel, Scott Buchanan, Nicholas Hanna, Maurice Buchbinder, Federico Asch, Gaby Weissman, Itsik Ben-Dor, Christian Shults, Hector M. Garcia-Garcia, Lowell F. Satler, Toby Rogers
- Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials
- Muhammad Shahzeb Khan, Soren Lund Kristensen, Muthiah Vaduganathan, Lars Kober, William T Abraham, Akshay S Desai, Scott D Solomon, Karl Swedberg, Kenneth Dickstein, Michael R Zile, Milton Packer, John JV. McMurray, Javed Butler
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?